715 related articles for article (PubMed ID: 19891248)
21. Non-antiarrhythmic drugs to prevent atrial fibrillation.
Moro C; Hernández-Madrid A; Matía R
Am J Cardiovasc Drugs; 2010; 10(3):165-73. PubMed ID: 20524718
[TBL] [Abstract][Full Text] [Related]
22. Statins and prevention of atrial fibrillation in patients with heart failure.
Liu T; Li G; Korantzopoulos P; Goudevenos JA
Int J Cardiol; 2009 Jul; 135(3):e83-4. PubMed ID: 18625529
[TBL] [Abstract][Full Text] [Related]
23. [The effect of inhibition of renin-angiotensin system on cardioversion success and recurrences of atrial fibrillation].
Doğan A; Akçay S
Anadolu Kardiyol Derg; 2009 Dec; 9(6):505-11. PubMed ID: 19965325
[TBL] [Abstract][Full Text] [Related]
24. [Pathophysiology of the renin-angiotensin-system in atrial fibrillation].
Heusch G; Schulz R
Dtsch Med Wochenschr; 2006 Apr; 131(15):817-20. PubMed ID: 16607602
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic prophylaxis of postoperative atrial fibrillation in patients undergoing cardiac surgery: beyond beta-blockers.
Davis EM; Packard KA; Hilleman DE
Pharmacotherapy; 2010 Jul; 30(7):749, 274e-318e. PubMed ID: 20575638
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant therapy for atrial fibrillation.
Mohammed KS; Kowey PR; Musco S
Future Cardiol; 2010 Jan; 6(1):67-81. PubMed ID: 20014988
[TBL] [Abstract][Full Text] [Related]
27. Statin therapy in the prevention and treatment of atrial fibrillation.
Lee YL; Blaha MJ; Jones SR
J Clin Lipidol; 2011; 5(1):18-29. PubMed ID: 21262503
[TBL] [Abstract][Full Text] [Related]
28. Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation.
Gillis AM; Morck M; Exner DV; Soo A; Rose MS; Sheldon RS; Duff HJ; Kavanagh KM; Mitchell LB; Wyse DG
Eur Heart J; 2008 Aug; 29(15):1873-80. PubMed ID: 18477727
[TBL] [Abstract][Full Text] [Related]
29. Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.
Qi WW; Liu T; Xu G; Li LF; Liang YZ; Ye L; Li GP
Trials; 2015 Aug; 16():336. PubMed ID: 26248619
[TBL] [Abstract][Full Text] [Related]
30. The changing face of postoperative atrial fibrillation prevention: a review of current medical therapy.
Mayson SE; Greenspon AJ; Adams S; Decaro MV; Sheth M; Weitz HH; Whellan DJ
Cardiol Rev; 2007; 15(5):231-41. PubMed ID: 17700382
[TBL] [Abstract][Full Text] [Related]
31. [Role of ACE-inhibitors in preventing atrial fibrillation relapses in normotensive patients].
Belluzzi F; Sernesi L; Centola M; Perlini S
Recenti Prog Med; 2009 Nov; 100(11):508-11. PubMed ID: 20066882
[TBL] [Abstract][Full Text] [Related]
32. Focus on renin-angiotensin system modulation and atrial fibrillation control after GISSI AF results.
Durin O; Pedrinazzi C; Inama G
J Cardiovasc Med (Hagerstown); 2010 Dec; 11(12):912-8. PubMed ID: 20729747
[TBL] [Abstract][Full Text] [Related]
33. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
34. Upstream therapy for atrial fibrillation in heart failure.
Goette A
Heart Fail Clin; 2013 Oct; 9(4):417-25, viii. PubMed ID: 24054475
[TBL] [Abstract][Full Text] [Related]
35. Tracing the origins of postoperative atrial fibrillation: the concept of oxidative stress-mediated myocardial injury phenomenon.
Elahi MM; Flatman S; Matata BM
Eur J Cardiovasc Prev Rehabil; 2008 Dec; 15(6):735-41. PubMed ID: 19020458
[TBL] [Abstract][Full Text] [Related]
36. Upstream effect for atrial fibrillation: still a dilemma?
Calò L; Martino A; Sciarra L; Ciccaglioni A; De Ruvo E; De Luca L; Sette A; Giunta G; Lioy E; Fedele F
Pacing Clin Electrophysiol; 2011 Jan; 34(1):111-28. PubMed ID: 21029134
[TBL] [Abstract][Full Text] [Related]
37. [Angiotensin receptor blockers and cardiac rhythm disorders].
Galinier M; Pathak A; Roncalli J
Arch Mal Coeur Vaiss; 2006; 99(7-8):745-7. PubMed ID: 17061457
[TBL] [Abstract][Full Text] [Related]
38. Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillation.
Lally JA; Gnall EM; Seltzer J; Kowey PR
J Cardiovasc Electrophysiol; 2007 Nov; 18(11):1222-8. PubMed ID: 17553070
[TBL] [Abstract][Full Text] [Related]
39. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention.
Savelieva I; Kakouros N; Kourliouros A; Camm AJ
Europace; 2011 May; 13(5):610-25. PubMed ID: 21515595
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
